Mediantechn - Asset Resilience Ratio
Mediantechn (ALMDT) has an Asset Resilience Ratio of 0.45% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check ALMDT PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2008–2025)
This chart shows how Mediantechn's Asset Resilience Ratio has changed over time. See net asset quality index of Mediantechn to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Mediantechn's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ALMDT market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €163.00K | 0.45% |
| Total Liquid Assets | €163.00K | 0.45% |
Asset Resilience Insights
- Limited Liquidity: Mediantechn maintains only 0.45% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Mediantechn Industry Peers by Asset Resilience Ratio
Compare Mediantechn's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
L&C Bio Co. Ltd
KQ:290650 |
Medical Devices | 2.14% |
|
Medacta Group SA
SW:MOVE |
Medical Devices | 0.86% |
|
Shenzhen New Industries Biomedical
SHE:300832 |
Medical Devices | 9.95% |
|
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317 |
Medical Devices | 10.88% |
|
Respiri Ltd
AU:RSH |
Medical Devices | 0.46% |
|
Human Xtensions Ltd
TA:HUMX |
Medical Devices | 29.83% |
|
Cochlear Ltd
AU:COH |
Medical Devices | 9.76% |
|
Anteris Technologies Global Corp
AU:AVR |
Medical Devices | 33.27% |
Annual Asset Resilience Ratio for Mediantechn (2008–2025)
The table below shows the annual Asset Resilience Ratio data for Mediantechn.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.45% | €163.00K ≈ $190.56K |
€35.87 Million ≈ $41.94 Million |
-0.17pp |
| 2024-12-31 | 0.62% | €151.00K ≈ $176.53K |
€24.37 Million ≈ $28.49 Million |
+0.28pp |
| 2023-12-31 | 0.34% | €123.00K ≈ $143.80K |
€35.94 Million ≈ $42.01 Million |
-0.23pp |
| 2022-12-31 | 0.58% | €200.00K ≈ $233.82K |
€34.75 Million ≈ $40.63 Million |
-78.90pp |
| 2021-12-31 | 79.47% | €39.25 Million ≈ $45.89 Million |
€49.39 Million ≈ $57.74 Million |
+14.62pp |
| 2020-12-31 | 64.86% | €16.40 Million ≈ $19.17 Million |
€25.28 Million ≈ $29.56 Million |
+63.98pp |
| 2019-12-31 | 0.87% | €141.00K ≈ $164.84K |
€16.12 Million ≈ $18.85 Million |
+0.36pp |
| 2018-12-31 | 0.52% | €94.00K ≈ $109.90K |
€18.15 Million ≈ $21.22 Million |
-0.09pp |
| 2017-12-31 | 0.60% | €206.00K ≈ $240.84K |
€34.14 Million ≈ $39.92 Million |
+0.34pp |
| 2016-12-31 | 0.26% | €123.00K ≈ $143.80K |
€46.55 Million ≈ $54.43 Million |
-0.01pp |
| 2015-12-31 | 0.27% | €91.00K ≈ $106.39K |
€33.55 Million ≈ $39.22 Million |
-0.05pp |
| 2014-12-31 | 0.32% | €58.00K ≈ $67.81K |
€17.87 Million ≈ $20.89 Million |
-10.31pp |
| 2011-12-31 | 10.64% | €1.11 Million ≈ $1.30 Million |
€10.47 Million ≈ $12.24 Million |
-49.54pp |
| 2010-12-31 | 60.17% | €2.81 Million ≈ $3.28 Million |
€4.67 Million ≈ $5.46 Million |
+6.27pp |
| 2009-12-31 | 53.90% | €2.71 Million ≈ $3.16 Million |
€5.02 Million ≈ $5.87 Million |
+29.99pp |
| 2008-12-31 | 23.92% | €1.39 Million ≈ $1.63 Million |
€5.83 Million ≈ $6.81 Million |
-- |
About Mediantechn
Median Technologies SA engages in providing medical imaging products and services for diagnosing and monitoring cancer patients in both routine clinical practice and clinical drug development with operations spanning in France, the United States, Canada, the United Kingdom, China, and internationally. The company offers iSee for imaging services in clinical trials; eyonis for non-invasive diagnos… Read more